Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
NCT05967182Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2024; status: recruiting.
02
Drugs
Beyond the preview
Go deeper on NCT05967182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967182.